Clinical trials
Treatment clinical trials
Below are recruiting treatment clinical trials, each written for real people, not researchers. We’re tracking 8,313 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07006298Recruiting
One-year outcomes in elderly patients with acute cholecystitis
This study looks at how older adults (70+) with acute gallbladder inflammation respond to different treatments over one year. It aims to find the best approach for this age group.
Alicante, AlicanteAges 70 years+ - NCT07012031RecruitingPhase 1/Phase 2
Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer
This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.
Sacramento, CaliforniaAges 18 years+ - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07010263RecruitingPhase 3
AK112 for limited-stage small cell lung cancer after chemoradiation
This study tests a new drug called AK112 (a bispecific antibody that blocks both PD-1 and VEGF) as a consolidation treatment to help prevent your limited-stage small cell lung cancer from coming back after you've finished chemoradiation. It's for people whose cancer has not grown following concurrent chemotherapy and radiation.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07008469Enrolling by invitationPhase 3
Long-term safety study of del-desiran for DM1
This study tests whether the drug del-desiran continues to be safe and effective for people with DM1 (myotonic dystrophy type 1) after they complete an earlier study. You'll receive the drug and have regular check-ups to see how you're doing.
Los Angeles, CaliforniaAges 16 years+ - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT07011186RecruitingPhase 1/Phase 2
TQB3909 and azacitidine for myeloid cancers
This trial tests a new oral drug, TQB3909, combined with a standard chemotherapy drug (azacitidine) for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination is safe and effective.
Bengbu, AnhuiAges 18 years+ - NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT06998888Recruiting
Remote monitoring for cancer patients on oral medications
This study tests whether a smartphone app (Caaring®) can help monitor cancer patients who take oral medications. If you are on an oral cancer treatment and comfortable using a smartphone, this trial may help you stay connected with your care team and manage side effects from home.
Boadilla del Monte, MadridAges 18 years+ - NCT07003646Recruiting
Treating acute pulmonary embolism with clot-dissolving or catheter procedures
This study looks at how well different treatments work for a blood clot in the lung (pulmonary embolism). It includes people who are getting or have already gotten a clot-dissolving medicine or a catheter procedure to remove the clot.
AarhusAges 18 years+ - NCT07011576RecruitingPhase 2
Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Denver, ColoradoAges 18 years+ - NCT07013292Recruiting
Omaveloxolone for swallowing issues in Friedreich's ataxia
This study looks at whether omaveloxolone (a medication) can help improve swallowing problems in people with Friedreich's ataxia. If you have been taking omaveloxolone for at least 6 months, your data may help researchers understand if it helps with swallowing.
Nice, Alpes MaritimesAges 16 years+ - NCT07013435Recruiting
Resilience training for lymphoma survivors
This study tests a program to help lymphoma survivors build resilience and improve long-term quality of life after treatment. It's a behavioral intervention, not a drug trial, that focuses on coping and well-being.
Boston, MassachusettsAges 18 years+ - NCT07009886Recruiting
Decision aid for advanced cancer patients considering more treatment
This study is testing a tool called TA-DA to help patients with advanced cancer and their caregivers make decisions about further treatment after at least two prior therapies. It aims to improve shared decision-making.
Houston, TexasAges 18 years+ - NCT07003763Recruiting
Electroacupuncture for depression in cancer patients
This trial tests whether electroacupuncture can help treat depression caused by cancer or its treatments. It may be a safe option for people who have not tried acupuncture before and are not currently receiving active cancer treatments.
ShanghaiAges 18–75 - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07007143RecruitingPhase 4
Blood thinner study after heart valve repair
This trial tests different blood-thinning medicines after a mitral valve repair procedure (TEER) in people who do not need long-term blood thinners. It aims to find the safest and most effective strategy to prevent blood clots.
Beijing, Beijing MunicipalityAges Any age - NCT07010484Recruiting
New imaging tests for polymyalgia rheumatica
This trial tests if new imaging methods can help diagnose and treat polymyalgia rheumatica (PMR). It may be for you if you're over 50, have pain in your shoulders or hips, and haven't taken steroids for PMR in the last 2 months.
AarhusAges 50 years+ - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT07006532Recruiting
Tocilizumab for chronic active antibody-mediated rejection
This trial tests whether the drug tocilizumab can help treat chronic active antibody-mediated rejection after a kidney transplant. It is for people whose kidney function is still fairly good and who have certain findings on biopsy.
TehranAges 18 years+ - NCT07004244RecruitingPhase 1
KRAS vaccine study for people with KRAS-mutated cancers
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Chengdu, SichuanAges 18 years+ - NCT07010237RecruitingPhase 2
Lower-dose immune therapy plus hetrombopag for older adults with severe aplastic anemia
This trial tests a milder version of immunosuppressive therapy combined with hetrombopag (a drug that helps bone marrow make blood cells) in people aged 65 years and older with severe aplastic anemia. The goal is to see if this approach is both safer and effective for older patients.
Tianjin, Tianjin MunicipalityAges 65 years+
Hear when a new Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for treatment?
- Yes. Clin2 currently lists 8,313 recruiting treatment studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a treatment trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a treatment trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.